Provides that every policy which provides coverage for hospital, surgical or medical care or provides reimbursement for laboratory tests or diagnostic X-rays shall provide coverage for testing of familial dysautonomia, Canavan's disease and Tay-Sachs; provides that in order to maintain the confidentiality of persons tested, receipt of acknowledgement from the testing facility shall be deemed sufficient evidence of testing.
Summary
Bill S06466 mandates that all insurance policies providing coverage for hospital, surgical, or medical care must include coverage for testing for familial dysautonomia, Canavan's disease, and Tay-Sachs. This requirement applies to both new policies and existing policies at their anniversary date, contingent upon evidence of insurability. The bill also stipulates that an acknowledgment from the laboratory performing the tests will suffice as proof of testing, ensuring confidentiality for individuals tested. Additionally, the coverage may be subject to standard deductibles and co-insurance arrangements.
Impact
The passage of this bill would amend the New York insurance law to require specific coverage for genetic testing related to familial dysautonomia, Canavan's disease, and Tay-Sachs. This change would enhance access to necessary medical testing for individuals at risk of these genetic conditions, potentially leading to earlier diagnosis and intervention. It would also set a precedent for how insurance policies handle genetic testing and could influence future legislation regarding coverage for other genetic disorders.
Sentiment
The sentiment surrounding Bill S06466 appears to be generally supportive, as it addresses important health issues related to genetic testing. However, there may be concerns regarding the implications for insurance costs and the administrative burden on insurance providers to implement these changes. The lack of recorded votes or committee discussions makes it difficult to gauge the full range of opinions.
Contention
Points of contention may arise regarding the financial implications for insurance companies and whether the mandated coverage could lead to increased premiums for policyholders. Some stakeholders may argue that while the intent is to provide essential health services, the potential cost burden on insurers could have broader impacts on the insurance market. There may also be discussions about the adequacy of the proposed confidentiality measures for individuals undergoing testing.
Same As
Provides that every policy which provides coverage for hospital, surgical or medical care or provides reimbursement for laboratory tests or diagnostic X-rays shall provide coverage for testing of familial dysautonomia, Canavan's disease and Tay-Sachs; provides that in order to maintain the confidentiality of persons tested, receipt of acknowledgement from the testing facility shall be deemed sufficient evidence of testing.
Provides that every policy which provides coverage for hospital, surgical or medical care or provides reimbursement for laboratory tests or diagnostic X-rays shall provide coverage for testing of familial dysautonomia, Canavan's disease and Tay-Sachs; provides that in order to maintain the confidentiality of persons tested, receipt of acknowledgement from the testing facility shall be deemed sufficient evidence of testing.
Provides that every policy which provides coverage for hospital, surgical or medical care or provides reimbursement for laboratory tests or diagnostic X-rays shall provide coverage for testing of familial dysautonomia, Canavan's disease and Tay-Sachs; provides that in order to maintain the confidentiality of persons tested, receipt of acknowledgement from the testing facility shall be deemed sufficient evidence of testing.
Provides that every policy which provides coverage for hospital, surgical or medical care or provides reimbursement for laboratory tests or diagnostic X-rays shall provide coverage for testing of familial dysautonomia, Canavan's disease and Tay-Sachs; provides that in order to maintain the confidentiality of persons tested, receipt of acknowledgement from the testing facility shall be deemed sufficient evidence of testing.
Provides that every health insurance policy which provides coverage for hospital, surgical or medical care shall provide coverage for the standard diagnostic testing for ovarian cancer upon the recommendation of a physician; provides that such standard diagnostic testing shall include a pelvic examination, a sonogram and a CA 125 blood test and related laboratory and diagnostic services.
Authorizes the department of health to establish a program for familial dysautonomia, Canavan's and Tay-Sachs disease screening and counseling and to provide grants and to enter into contracts with public and non-profit private entities to assist in such program; provides that participation in such program shall be voluntary and all information shall be confidential.
Provides for mandatory health insurance coverage for coronary artery calcium diagnostic testing upon the recommendation of a health care provider; makes related provisions.
Provides that insurance policies which provide hospital, surgical or medical coverage shall provide coverage for hysterectomies; provides that such coverage shall include inpatient hospital coverage for a minimum period of seventy-two hours after surgery.
Provides that clinical laboratories may provide laboratory testing at the request of individuals, without a practitioner order or prescription, for certain types of cholesterol.